AnaptysBioNASDAQ: ANAB

AnaptysBio (ANAB) experienced a surge in stock price during the last trading session with higher than usual trading volume. Recent changes in earnings estimates indicate that the stock may continue to show strength in the future.

Although the stock market has dipped slightly from its recent peak, the S&P 500 is still up 7.4% in 2024. Technology stocks, particularly Super Micro Computer (NASDAQ: SMCI), have shown strong performance with a 216% increase.

A large bank started covering the biotech company, advising investors to buy and suggesting that the stock price could potentially more than double.

AnaptysBio (ANAB) has experienced positive changes in earnings estimates in the last month and is part of a robust industry.

AnaptysBio, Inc. (ANAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for AnaptysBio, Inc. (ANAB) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.59 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to loss of $0.93 per share a year ago.

SAN DIEGO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, will participate in a panel discussion at TD Cowen's 44th Annual Health Care Conference.

AnaptysBio, Inc. (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.